Philippe Calais
Vorsitzender bei TRANSCODE THERAPEUTICS, INC.
Vermögen: 84 $ am 30.04.2024
Aktive Positionen von Philippe Calais
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TRANSCODE THERAPEUTICS, INC. | Independent Dir/Board Member | 18.02.2021 | - |
Vorsitzender | 18.02.2021 | - | |
Direktor/Vorstandsmitglied | 01.10.2018 | 18.02.2021 | |
Phileas Pharma, Inc. | Vorsitzender | 01.05.2019 | - |
Gründer | 01.05.2019 | - | |
MatriSys Bioscience, Inc.
MatriSys Bioscience, Inc. BiotechnologyHealth Technology MatriSys Bioscience, Inc. engages in the development of biologic therapeutics. It offers therapies for dermatology and skin care conditions including atopic dermatitis, rosacea, psoriasis, acne, and skin infections. The company was founded by Mark S. Wilson and Richard L. Gallo in 2015 and is headquartered in La Jolla, CA. | Direktor/Vorstandsmitglied | - | - |
Vorstandsvorsitzender | - | - | |
Präsident | - | - |
Karriereverlauf von Philippe Calais
Ehemalige bekannte Positionen von Philippe Calais
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
COHBAR, INC. | Direktor/Vorstandsmitglied | 06.06.2018 | 16.06.2020 |
Vorstandsvorsitzender | 07.12.2018 | 15.05.2019 | |
Independent Dir/Board Member | 06.06.2018 | 07.12.2018 | |
Isarna Therapeutics BV
Isarna Therapeutics BV Financial ConglomeratesFinance Isarna Therapeutics BV is an investment holding Dutch company. The private company is based in Zevenbergen, Netherlands. | Vorstandsvorsitzender | 01.03.2012 | 01.06.2018 |
Präsident | 01.03.2012 | 01.06.2018 | |
Autotelic, Inc.
Autotelic, Inc. Pharmaceuticals: MajorHealth Technology Autotelic, Inc. manufactures therapeutics drugs. Its Therapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. The company was founded in 2013 and is headquartered in Costa Mesa, CA. | Direktor/Vorstandsmitglied | 01.06.2016 | 01.06.2018 |
ADHERA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.01.2017 | 02.05.2018 |
Independent Dir/Board Member | 01.01.2017 | 02.05.2018 | |
Univalor, Inc.
Univalor, Inc. Miscellaneous Commercial ServicesCommercial Services Univalor, Inc. engages in the provision of research and development services. The company was founded on April 27, 2001 and is headquartered in Montréal, Canada. | Vorstandsvorsitzender | 01.04.2011 | 01.02.2012 |
Präsident | 01.04.2011 | 01.02.2012 | |
Cite Des Biotechs De Laval | Direktor/Vorstandsmitglied | 01.02.2002 | 01.02.2012 |
░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von Philippe Calais
Université François-Rabelais de Tours | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Kanada | 7 |
Frankreich | 3 |
Operativ
Director/Board Member | 10 |
President | 5 |
Chief Executive Officer | 5 |
Sektoral
Health Technology | 10 |
Commercial Services | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
COHBAR, INC. | Health Technology |
TRANSCODE THERAPEUTICS, INC. | Health Technology |
ADHERA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 14 |
---|---|
BELLUS Health, Inc.
BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
Université Pierre et Marie Curie | Consumer Services |
Neurochem (International) Ltd.
Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Commercial Services |
Servier Canada, Inc.
Servier Canada, Inc. Pharmaceuticals: MajorHealth Technology Servier Canada, Inc. provides healthcare services. It manufactures pharmaceuticals for cardiology, diabetes, depression, venous disease and menopause. The company was founded in 1978 and is headquartered in Quebec, Canada. | Health Technology |
Univalor, Inc.
Univalor, Inc. Miscellaneous Commercial ServicesCommercial Services Univalor, Inc. engages in the provision of research and development services. The company was founded on April 27, 2001 and is headquartered in Montréal, Canada. | Commercial Services |
Medpharmgene, Inc.
Medpharmgene, Inc. Miscellaneous Commercial ServicesCommercial Services Medpharmgene, Inc. provides commercial physical research services. The private company is based in Montréal, Canada and was founded in 2001. | Commercial Services |
MatriSys Bioscience, Inc.
MatriSys Bioscience, Inc. BiotechnologyHealth Technology MatriSys Bioscience, Inc. engages in the development of biologic therapeutics. It offers therapies for dermatology and skin care conditions including atopic dermatitis, rosacea, psoriasis, acne, and skin infections. The company was founded by Mark S. Wilson and Richard L. Gallo in 2015 and is headquartered in La Jolla, CA. | Health Technology |
Phileas Pharma, Inc. | |
Isarna Therapeutics BV
Isarna Therapeutics BV Financial ConglomeratesFinance Isarna Therapeutics BV is an investment holding Dutch company. The private company is based in Zevenbergen, Netherlands. | Finance |
Cite Des Biotechs De Laval | |
Cognisense | |
Autotelic, Inc.
Autotelic, Inc. Pharmaceuticals: MajorHealth Technology Autotelic, Inc. manufactures therapeutics drugs. Its Therapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. The company was founded in 2013 and is headquartered in Costa Mesa, CA. | Health Technology |
- Börse
- Insiders
- Philippe Calais
- Erfahrung